×







We sell 100% Genuine & New Books only!

Disease Control Priorities Third Edition (Volume 3) Cancer at Meripustak

Disease Control Priorities Third Edition (Volume 3) Cancer by Hellen Gelband Jha Prabhat Rengaswamy Sankaranarayanan & Susan Horton, World Bank Publications


  • Price: ₹ 3021.00/- [ 7.00% off ]

    Seller Price: ₹ 2809.00

Estimated Delivery Time : 4-5 Business Days

Sold By: Meripustak      Click for Bulk Order

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

We deliver across all postal codes in India

Orders Outside India


Add To Cart


Outside India Order Estimated Delivery Time
7-10 Business Days


  • We Deliver Across 100+ Countries

  • MeriPustak’s Books are 100% New & Original
  • General Information  
    Author(s)Hellen Gelband Jha Prabhat Rengaswamy Sankaranarayanan & Susan Horton
    PublisherWorld Bank Publications
    Edition3rd Edition
    ISBN9784648034993
    Pages360
    BindingPaperback with Sewin
    LanguageEnglish
    Publish YearDecember 2014

    Description

    World Bank Publications Disease Control Priorities Third Edition (Volume 3) Cancer by Hellen Gelband Jha Prabhat Rengaswamy Sankaranarayanan & Susan Horton

    Volume 3, Cancer, presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control cancers. The DCP3 evaluation of cancer will indicate where cancer treatment is ineffective and wasteful, and offer alternative cancer care packages that are cost-effective and suited to low-resource settings. Main messages from the volume include:Quality matters in all aspects of cancer treatment and palliation.Cancer registries that track incidence, mortality, and survival, paired with systems to capture causes of death are important to understanding the national cancer burden and the effect of interventions over time.Effective interventions exist at a range of prices. Adopting “resource appropriate" measures which allow the most effective treatment for the greatest number of people will be advantageous to countries.Prioritizing resources toward early stage and curable cancers is likely to have the greatest health impact in low income settings.Research prioritization is no longer just a global responsibility.Providing cancer treatment requires adequate numbers of trained healthcare professionals and infrastructure beyond what is available in most LMICs, especially low income countries. Careful patient monitoring is a requirement of good quality cancer care and this often involves laboratory tests in addition to clinical examination. Even if financing were immediately available to build or expand a cancer control system, reaching capacity will take many years.



    Book Successfully Added To Your Cart